Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSU

Key Takeaways

• Novartis will present new Phase III REMIX-1/-2 analyses of remibrutinib (Rhapsido) in chronic spontaneous urticaria (CSU) at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

• Phase II data in IgE-mediated peanut allergy will be featured in an oral session, with a Phase III food allergy program planned for H2 2026.

• Remibrutinib remains in development across multiple immune-mediated conditions, including chronic inducible urticaria and hidradenitis suppurativa.

New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.

The program includes new analyses in chronic spontaneous urticaria (CSU) and early clinical data in IgE-mediated peanut allergy, according to a press release from Novartis. Study investigators will present updated analyses from the Phase III REMIX-1 and REMIX-2 trials examing disease control and early symptom relief. Additional health economics research aims to connect and illuminate health care resource use by level of disease control in US patients with CSU. A separate abstract explores a novel autoantibody panel for molecular diagnosis.

Abstracts accepted for presentation include:

• Efficacy and safety of remibrutinib for individuals with IgE-mediated peanut allergy (Abstract #563, Oral, February 28).

• REMIX-1/-2 analysis of urticaria disease control (Abstract #822, Poster, March 1).

• Early symptom relief in pooled REMIX-1/-2 data (Abstract #039, Poster, February 27).

• Health care resource utilization in CSU (Abstract #021, Poster, February 27).

• Autoantibody panel in CSU diagnosis (Abstract #022, Poster, February 27).

Source: Novartis press release. February 23, 2026.